As of February 6, 2026, the global financial landscape is being reshaped by an unprecedented "wall of capital." After nearly two years of stagnation caused by valuation gaps and high borrowing costs, the private equity industry has entered a transformative period of deployment. With a record-shattering $3.2 trillion in
The long-awaited "deal drought" has officially broken. As of early February 2026, the American financial landscape is being reshaped by a massive resurgence in corporate deal-making, punctuated by a staggering 111.5% year-over-year increase in transactions valued over $100 million at the close of 2025. This tidal wave of capital
In a move that has sent shockwaves through the medical technology sector, Boston Scientific (NYSE:BSX) announced on January 15, 2026, a definitive agreement to acquire Penumbra (NYSE:PEN) for approximately $14.5 billion. The deal represents the largest acquisition for Boston Scientific in over two decades, signaling a transformative
The "Great Hesitation" in global finance has officially come to an end. In the opening weeks of 2026, the private equity landscape has undergone a dramatic transformation, shifting from two years of defensive posturing to a full-scale dealmaking renaissance. Driven by a record-shattering $2 trillion in "dry powder" and a
February 5, 2026 The medical technology landscape experienced a seismic shift this week as one of its long-standing titans, Boston Scientific (NYSE: BSX), faced a "valuation reset" that has left investors and analysts debating the future of high-growth medtech. For over a decade, Boston Scientific has been the gold standard for consistent execution and category [...]
In a move that has sent shockwaves through the healthcare sector, Boston Scientific (NYSE:BSX) has announced a definitive agreement to acquire Penumbra (NYSE:PEN) for approximately $14.5 billion. The deal, announced in mid-January and currently the talk of Wall Street as we move into February 2026, marks one
MARLBOROUGH, Mass. — In a move that has sent shockwaves through the medical technology landscape, Boston Scientific (NYSE: BSX) announced on January 15, 2026, a definitive agreement to acquire Penumbra (NYSE: PEN) for an enterprise value of approximately $14.5 billion. The deal, representing Boston Scientific’s largest acquisition in over
In a move that has sent shockwaves through the healthcare sector, Boston Scientific Corporation (NYSE: BSX) announced on January 15, 2026, its definitive agreement to acquire Penumbra, Inc. (NYSE: PEN) for approximately $14.5 billion. The deal represents one of the most significant consolidations in the history of the medical
The U.S. stock market reached a historic milestone on January 27, 2026, as the S&P 500 (NYSEARCA:SPY) climbed to a fresh all-time high of 6,980.75, tantalizingly close to the psychologically significant 7,000 level. Driven by a surge in the Nasdaq Composite (NASDAQ:QQQ), which
As of January 26, 2026, the American corporate landscape is undergoing its most radical transformation in a generation. Following a two-year period of high-interest-rate hibernation, the United States merger and acquisition (M&A) market has roared back to life with a ferocity that has caught even seasoned Wall Street analysts
As the Federal Reserve transitions from its long-standing "higher-for-longer" stance to a deliberate cycle of monetary easing, the U.S. equity market is witnessing a profound shift in leadership. For the first time in years, the spotlight has moved away from the tech behemoths of the "Magnificent Seven" and onto
The past six months have been a windfall for Penumbra’s shareholders. The company’s stock price has jumped 55.5%, setting a new 52-week high of $355.93 per share. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Expensive stocks often command premium valuations because the market thinks their business models are exceptional.
However, the downside is that high expectations are already baked into their prices, leaving little room for error if they stumble even slightly.
As 2026 begins, the global mergers and acquisitions (M&A) market is witnessing a profound "renaissance," driven by a confluence of stabilizing interest rates, record levels of corporate cash, and a strategic pivot toward high-growth technology. Morgan Stanley (NYSE: MS) recently released a bullish outlook for the year, projecting a
Shares of medical device company Penumbra (NYSE:PEN)
jumped 12.1% in the afternoon session after the company agreed to be acquired by Boston Scientific in a deal valued at approximately $14.5 billion.
MARLBOROUGH, MA – In a move that has sent shockwaves through the medical device sector, Boston Scientific Corporation (NYSE:BSX) announced today, January 15, 2026, a definitive agreement to acquire Penumbra, Inc. (NYSE:PEN) for approximately $14.5 billion. The blockbuster deal, the largest in the industry since the early 2020s,
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns
as healthcare stocks have gained 18.7% over the past six months while the S&P 500 was up 11.1%.
A cash-heavy balance sheet is often a sign of strength, but not always.
Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets.
But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
The stocks featured in this article are seeing some big returns.
Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
Looking back on medical devices & supplies - cardiology, neurology, vascular stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Penumbra (NYSE:PEN) and its peers.
